Welcome to our dedicated page for Aura Biosciences SEC filings (Ticker: AURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aura Biosciences’ 10-K can run hundreds of pages of scientific data, trial protocols, and detailed risk factors—information critical to gauging cash runway and FDA timelines yet daunting to sift through. If you have ever asked, “How do I navigate Aura Biosciences SEC filings explained simply?” you are not alone. Complex biotech disclosures demand more than a quick skim.
Stock Titan’s AI reads every word the moment a document hits EDGAR, then delivers plain-English highlights. Whether it is the Aura Biosciences quarterly earnings report 10-Q filing, an Aura Biosciences 8-K material events explained, or Aura Biosciences annual report 10-K simplified, our platform pinpoints trial enrollment updates, research spend, and pivotal safety data. Need alerts on management activity? Receive Aura Biosciences Form 4 insider transactions real-time so you can track Aura Biosciences executive stock transactions Form 4 before the market reacts. You will also find the full Aura Biosciences proxy statement executive compensation with AI commentary on incentive alignment.
Investors use these insights to monitor bel-sar’s clinical milestones, compare quarter-over-quarter R&D expenses, and spot insider confidence trends. Our coverage spans every form—from S-1 amendments to the smallest 424B5—updated instantly and searchable by keyword or question such as “understanding Aura Biosciences SEC documents with AI” or “Aura Biosciences earnings report filing analysis.” Stop scrolling through PDFs; start asking targeted questions and get concise answers backed by complete filings and AI-powered context. All Aura Biosciences insider trading Form 4 transactions and more are one click away, saving hours while keeping you fully informed.
Aura Biosciences (AURA) Form 4: Director Sapna Srivastava reported new equity awards dated 17 June 2025.
- 13,000 restricted stock units (RSUs) were granted at no cost; they vest on the earlier of 17 June 2026 or the next annual shareholder meeting, contingent on continued service.
- 17,000 stock options were issued with a $6.18 exercise price, identical vesting trigger, and an expiration date of 17 June 2035.
Following the transaction, Srivastava directly owns 23,500 common shares and 17,000 options. No shares were sold, and the awards constitute routine director compensation that modestly increases ownership alignment without immediate cash impact.
Form 4 overview: On 17 June 2025, Aura Biosciences (AURA) director Antony C. Mattessich reported equity-based awards that increase his direct ownership in the company.
- Restricted stock units: 13,000 RSUs were granted at no cost. The units convert 1-for-1 into common shares and vest in full on the earlier of 17 June 2026 or the next annual shareholder meeting, contingent on continued service.
- Stock options: 17,000 options with a US$6.18 exercise price were awarded on the same date. The options vest in full on the same schedule and expire 17 June 2035.
- Post-transaction holding: Mattessich now directly owns 23,500 common shares (includes previously held shares plus the new RSUs).
No open-market purchases or sales occurred; the filing reflects routine director equity compensation aligned with Aura’s 2021 Stock Option and Incentive Plan.
On 17 June 2025 Aura Biosciences, Inc. (Nasdaq: AURA) held its 2025 Annual Meeting of Stockholders, as reported in the Form 8-K filed 18 June 2025 under Item 5.07.
Participation: 38,863,371 common shares—or 77.3 % of the 50,268,758 shares entitled to vote—were present or represented by proxy.
Proposal 1 – Election of Class I Directors (terms through 2028)
- Elisabet de los Pinos, Ph.D.: 28,961,014 for; 985,262 withheld; 8,917,095 broker non-votes
- Giovanni Mariggi, Ph.D.: 29,179,073 for; 767,203 withheld; 8,917,095 broker non-votes
Both nominees were duly elected.
Proposal 2 – Ratification of Independent Auditor
- Ernst & Young LLP ratified for fiscal year ending 31 Dec 2025 with 38,623,566 for; 232,989 against; 6,816 abstentions; zero broker non-votes.
No additional matters were submitted. The filing contains no financial performance metrics, guidance, or transactional disclosures; therefore the event is considered routine corporate governance with limited immediate financial impact.
FAQ
What is the current stock price of Aura Biosciences (AURA)?
What is the market cap of Aura Biosciences (AURA)?
What is Aura Biosciences, Inc.?
How does Aura Biosciences' precision therapy approach differ from traditional treatments?
What are the primary therapeutic areas targeted by Aura Biosciences?
How does Aura Biosciences ensure the preservation of organ function in its treatments?
What stage is the company’s lead candidate bel-sar currently in?
How does Aura Biosciences address the challenges of cancer treatment?
What distinguishes Aura Biosciences from its competitors?
What is the company’s approach to maintaining scientific rigor in its development programs?
